Advancing new vaccines against pandemic influenza in low-resource countries

Scorza, Francesco Berlanda

doi:10.1016/j.vaccine.2017.03.094

Cited by 8 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A WIv was on the market in europe until recently but is no longer in use 104 . Currently, WIvs are mostly developed and manufactured by low-income and middle-income countries owing to the less complicated downstream processing required for these vaccines 183 . Inactivated (and recombinant HA-based) vaccines are injected intramuscularly or intradermally and typically without adjuvant (with a few exceptions).…”

Section: Responses To Vaccinationmentioning

confidence: 99%

The human antibody response to influenza A virus infection and vaccination

2019

View full text Add to dashboard Cite

The adaptive immune response to influenza virus infection is multifaceted and complex, involving antibody and cellular responses at both systemic and mucosal levels. Immune responses to natural infection with influenza virus in humans are relatively broad and long-lived, but influenza viruses can escape from these responses over time owing to their high mutation rates and antigenic flexibility. Vaccines are the best available countermeasure against infection, but vaccine effectiveness is low compared with other viral vaccines, and the induced immune response is narrow and short-lived. Furthermore, inactivated influenza virus vaccines focus on the induction of systemic IgG responses but do not effectively induce mucosal IgA responses. Here, I review the differences between natural infection and vaccination in terms of the antibody responses they induce and how these responses protect against future infection. A better understanding of how natural infection induces broad and long-lived immune responses will be key to developing next-generation influenza virus vaccines.

show abstract

Section: Responses To Vaccinationmentioning

confidence: 99%

The human antibody response to influenza A virus infection and vaccination

2019

View full text Add to dashboard Cite

show abstract

“…The successful development of IB160 production by Butantan Institute is strategic for the preparedness of pandemic influenza to complement the capacity of the H7N9 antigen production in alignment with WHO strategies [24]. The challenge in the next years is to establish the scale up and commercial production conditions for IB160 to achieve self-sufficiency in case of a pandemic influenza in Brazil as well as a potential safeguard for neighboring countries in Latin America.…”

Section: Plos Onementioning

confidence: 99%

“…The World Health Organization (WHO) encourages countries to develop and implement national pandemic preparedness plans to mitigate the health and social effects of a potential pandemic [23][24]. Increasing global pandemic influenza vaccine manufacturing capacity is considered strategic by WHO and the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Human and Health Services (HHS) [8,24]. However, the limited financial and technical resources in developing countries make the preparedness for a pandemic more challenging in these regions [23].…”

Section: Introductionmentioning

confidence: 99%

Preparedness against pandemic influenza: Production of an oil-in-water emulsion adjuvant in Brazil

et al. 2020

View full text Add to dashboard Cite

Increasing pandemic influenza vaccine manufacturing capacity is considered strategic by WHO. Adjuvant use is key in this strategy in order to spare the vaccine doses and by increasing immune protection. We describe here the production and stability studies of a squalene based oil-in-water emulsion, adjuvant IB160, and the immune response of the H7N9 vaccine combined with IB160. To qualify the production of IB160 we produced 10 consistency lots of IB160 and the average results were: pH 6.4±0.05; squalene 48.8±.0.03 mg/ ml; osmolality 47.6±6.9 mmol/kg; Z-average 157±2 nm, with polydispersity index (PDI) of 0.085±0.024 and endotoxin levels <0.5 EU/mL. The emulsion particle size was stable for at least six months at 25˚C and 24 months at 4-8˚C. Two doses of H7N9 vaccine formulated at 7.5 μg/dose or 15 μg/dose with adjuvant IB160 showed a significant increase of hemagglutination inhibition (HAI) titers in sera of immunized BALB/c mice when compared to control sera from animals immunized with the H7N9 antigens without adjuvant. Thus the antigensparing capacity of IB160 can potentially increase the production of the H7N9 pandemic vaccine and represents an important achievement for preparedness against pandemic influenza and a successful North (IDRI) to South (Butantan Institute) technology transfer for the production of the adjuvant emulsion IB160.

show abstract

“…These results are encouraging in that a microgram-dose vaccine was consistently immunogenic and had an acceptable safety profile similar to other adjuvanted vaccines. Additionally, it is important to note that induction of antibodies for avian strains has proven to be very challenging in clinical trials with traditional protein antigen based vaccines as naïve individuals respond poorly to split virus vaccines containing H5 or H7 HAs [ 52 , 53 , 54 ].…”

Section: Rna Vaccines Against Influenza Virus—vaccine Types Preclmentioning

confidence: 99%

New Kids on the Block: RNA-Based Influenza Virus Vaccines

Scorza

Pardi

2018

Vaccines

View full text Add to dashboard Cite

RNA-based immunization strategies have emerged as promising alternatives to conventional vaccine approaches. A substantial body of published work demonstrates that RNA vaccines can elicit potent, protective immune responses against various pathogens. Consonant with its huge impact on public health, influenza virus is one of the best studied targets of RNA vaccine research. Currently licensed influenza vaccines show variable levels of protection against seasonal influenza virus strains but are inadequate against drifted and pandemic viruses. In recent years, several types of RNA vaccines demonstrated efficacy against influenza virus infections in preclinical models. Additionally, comparative studies demonstrated the superiority of some RNA vaccines over the currently used inactivated influenza virus vaccines in animal models. Based on these promising preclinical results, clinical trials have been initiated and should provide valuable information about the translatability of the impressive preclinical data to humans. This review briefly describes RNA-based vaccination strategies, summarizes published preclinical and clinical data, highlights the roadblocks that need to be overcome for clinical applications, discusses the landscape of industrial development, and shares the authors’ personal perspectives about the future of RNA-based influenza virus vaccines.

show abstract

Advancing new vaccines against pandemic influenza in low-resource countries

Cited by 8 publications

References 30 publications

The human antibody response to influenza A virus infection and vaccination

The human antibody response to influenza A virus infection and vaccination

Preparedness against pandemic influenza: Production of an oil-in-water emulsion adjuvant in Brazil

New Kids on the Block: RNA-Based Influenza Virus Vaccines

Contact Info

Product

Resources

About